Amgen Inc. vs Verona Pharma plc: SG&A Expense Trends

SG&A Expense Trends: Amgen Inc. vs Verona Pharma plc

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Amgen Inc. and Verona Pharma plc from 2014 to 2023. Over this period, Amgen's SG&A expenses have shown a steady increase, peaking at approximately $6.2 billion in 2023, marking a 31% rise from 2014. In contrast, Verona Pharma's expenses, though significantly lower, have surged by over 2,600%, reaching nearly $50 million in 2023. This stark difference highlights the contrasting scales and growth strategies of these two companies. While Amgen's expenses reflect its established market presence, Verona's rapid increase suggests aggressive expansion efforts. These insights provide a window into the strategic priorities of these pharmaceutical giants, offering valuable lessons for investors and industry analysts alike.